^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic lymphocytic leukemia/Small lymphocytic lymphoma: Suggested treatment regimens...CLL/SLL with del(17p)/TP53 mutation…relapsed/refractory therapy…other recommended regimens…lenalidomide ± rituximab
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

    Published date:
    02/10/2013
    Excerpt:
    Patients with relapsed or refractory CLL were enrolled onto a phase II study of lenalidomide and rituximab...The ORR was 53% for patients with chromosome 17p deletion...
    DOI:
    10.1200/JCO.2012.42.8623
    Trial ID:
    NCT00759603